Geron | Working to change the course of blood cancers
Geron is tirelessly pursuing blood cancer treatments with the potential to extend and enhance lives.
Geron Corporation - Investors & Media
2024年12月10日 · Geron is a commercial-stage biopharmaceutical company with a first-in-class telomerase inhibitor that is approved in the United States for the treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia.
Geron Corporation - Geron Announces FDA Approval of RYTELO™ …
2024年6月6日 · Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO™ (imetelstat) is FDA-approved for the treatment of adult patients with lower-risk MDS with transfusion dependent anemia.
Our story continues to evolve - Geron
At Geron, our innovative and collaborative culture has been the foundation of our commitment to advancing telomerase inhibition as a treatment with the potential to change lives for the better by changing the course of blood cancers.
Our tireless pursuit | Geron
With a seasoned leadership team with world-class expertise spanning research, clinical development, regulatory, manufacturing and commercial experience in hematologic malignancies, Geron is prepared to deliver on our mission to change lives by changing the course of …
Geron Corporation - Geron Corporation Announces Up to $375 …
2024年11月7日 · Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO™ (imetelstat) is approved in the United States for the treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion dependent anemia.
Geron Corporation Reports Third Quarter 2024 Financial Results …
2024年11月7日 · Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO™ (imetelstat) is approved in the United States for the treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion dependent anemia.
Geron Corporation - Geron Announces Positive Top-Line Results …
2023年1月4日 · Geron is a late-stage biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies. The Company’s investigational first-in-class telomerase inhibitor, imetelstat, harnesses Nobel Prize-winning science in a treatment that may alter the underlying drivers of disease.
Geron Announces FDA Acceptance of New Drug Application for …
2023年8月21日 · Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has accepted the filing of Geron’s New Drug Application (NDA) for imetelstat, its first-in-class telomerase inhibitor, for the treatment of transfusion-dependent anemia in patients with ...
Clinical trials exploring imetelstat - Geron
Geron sponsored trials IMpactMF, our pivotal Phase 3 clinical trial in JAK inhibitor relapsed/refractory MF, is an open label, 2:1 randomized, controlled clinical trial of imetelstat to evaluate a potential improvement in overall survival compared to best available therapy.